ReviewInfection & chemotherapy2024
Guidelines for Antibacterial Treatment of Carbapenem-Resistant Enterobacterales Infections.
Review in Infection & chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical outcomes of carbapenem therapy in OXA-48-producing Enterobacterales infections: a French multicentre cohort, systematic review, and meta-analysis.Emerging microbes & infections · 2026Pooled it
- Real-world effectiveness and treatment costs of ceftazidime-avibactam versus colistin-meropenem for ICU-acquired MDR gram-negative infections in liver transplant recipients.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Novel β-Lactam/β-Lactamase Inhibitors Versus Best Available Therapy on the Mortality-Related Carbapenem-Resistant Enterobacterales Infection: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2026Review
- Outcome of Ceftazidime/Avibactam Versus Alternative Antibiotics for Treatment of Carbapenem-ResistantJournal of Korean medical science · 2026Article
- Microbiological Profile of Pathogens Among Patients at a Tertiary Care Hospital in Mumbai, India.Cureus · 2026Article
- NDM-ProducingJournal of clinical medicine · 2026Article
- Ceftazidime-Avibactam Effectiveness in Carbapenem-Resistant Enterobacterales Bacteremia: A Retrospective Cohort Study in Korea.Journal of Korean medical science · 2026Article
- Treatment Options for Metallo-Beta-Lactamase-ProducingInternational journal of molecular sciences · 2026Review
- Comparison of outcomes of KPC-producing Enterobacterales bloodstream infections treated with ceftazidime-avibactam and other conventional antibiotics: retrospective single-center study.Microbiology spectrum · 2026Observational
- Carbapenem resistance and hypervirulence iniScience · 2026Review
- Novel Insights into Carbapenem Resistance: Mechanisms, Diagnostics, and Future Directions.Antibiotics (Basel, Switzerland) · 2026Review
- Early procalcitonin kinetics as an independent predictor of mortality in multi-drug resistant Klebsiella spp. bloodstream infections: a retrospective cohort study.BMC infectious diseases · 2026Observational
- Molecular Insights into Carbapenem Resistance inInternational journal of molecular sciences · 2026Review
- Comparative analysis of treatment outcomes and risk factors associated with different combination antimicrobial regimens in patients with multidrug-resistant Acinetobacter baumannii pneumonia.Frontiers in cellular and infection microbiology · 2026Article
- Neonatal-Onset Chronic Granulomatous Disease Presenting With Recurrent Culture-Negative Meningitis: A Case Report and Diagnostic Considerations.Case reports in immunology · 2026Article
- Characteristics and outcomes of patients treated with tigecycline for MDR gram-negative infections: a retrospective cohort study.Frontiers in cellular and infection microbiology · 2026Article
- Characterization and genome analyses of the novel phages targeting extraintestinal Escherichia coli clones ST131 and ST410.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- "Global divide in carbapenem resistance and hypervirulence of Klebsiella pneumonia: comparing trends in India and developed nations"- a comprehensive review.The Journal of antibiotics · 2025Review
- Standardized pre-bronchoscopy mechanical power and KPC resistance as predictors of mortality in ventilated ICU patients: a retrospective cohort study.Frontiers in medicine · 2025Article
- Emergence of carbapenem-resistantFrontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
This guideline aims to promote the prudent use of antibacterial agents for managing carbapenem-resistant Enterobacterales (CRE) infections in clinical practice in Korea. The general section encompasses recommendations for the management of common CRE infections and diagnostics, whereas each specific section is structured with key questions that are focused on antibacterial agents and disease-specific approaches. This guideline covers both currently available and upcoming antibacterial agents in Korea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.